RxDoctor Payments Data

Mark Abrams, MD

Otolaryngology · Rock Hill, SCNPI 1508827825

Payments from drug & device makers

$2,796in general payments, 2019–2025

Across 82 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$743
  • AbbVie$461
  • Optinose US, Inc.$347
  • Aerin Medical Inc.$319
  • Regeneron Healthcare Solutions, Inc.$249
  • Pfizer$182
  • plus $495 from 12 others

What the payments were for

  • Food & beverage$2,796100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,796 in reported general payments places this provider in the 60th percentile of 180 otolaryngology providers in South Carolina.

See all otolaryngology providers in South Carolina

Medicare billing

Part B allowed, 2024
$178,669
Medicare patients
715
Services billed
3,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate15$17,598
Famotidine912$17,048
Omeprazole526$6,832
Ipratropium Bromide138$6,186
Fluticasone Propionate271$5,880
Dexlansoprazole DrDexlansoprazole12$4,004
Albuterol Sulfate HfaAlbuterol Sulfate156$3,358
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth23$2,501
Pantoprazole Sodium181$2,186
Pilocarpine Hcl18$1,428
Esomeprazole Magnesium18$937
Prednisone554$730
Montelukast Sodium48$518
Minocycline Hcl45$431
Levocetirizine Dihydrochloride26$427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$182$17,59815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 180 otolaryngology providers in South Carolina.

Other otolaryngology in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →